Clinic
Essent PRMC LP
Essent PRMC LP was paid $3.71M by Medicaid between Jan 2018 and Nov 2024, across 67 billing codes. Its largest line is 99283, emergency room visit (moderate) — 41% of everything it billed.
33Billing provider infoESSENT PRMC LP
PARIS, TX 75460
PARIS, TX 75460
33aNPI1063411767assigned 07/15/2005
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$3.71M
24GClaims74,464
24DCodes billed67
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#95 of 320
Median peer was paid$205K
This provider vs. median18×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 43 | $6K | |
| 2019 | 292 | $30K | |
| 2020 | 1,348 | $107K | |
| 2021 | 22,228 | $664K | |
| 2022 | 22,720 | $930K | |
| 2023 | 19,507 | $1.35M | |
| 2024incomplete | 8,326 | $616K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 41% | 11,337 | 10,869 | $1.51M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 30% | 5,021 | 4,730 | $1.13M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 2,062 | 1,880 | $524K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.5% | 3,391 | 3,151 | $165K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 403 | 397 | $74K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.8% | 502 | 221 | $67K |
| 80053 | Comprehensive metabolic panel | 1.2% | 5,526 | 4,949 | $43K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 5,519 | 4,816 | $32K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 673 | 633 | $30K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,568 | 1,251 | $18K |
| 81001 | <1% | 4,983 | 4,655 | $15K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,506 | 1,367 | $15K |
55 more codes
| 87400 | <1% | 479 | $12K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 166 | $12K |
| 87802 | <1% | 389 | $10K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,529 | $8K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 429 | $5K |
| 87088 | <1% | 1,327 | $5K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 141 | $3K |
| 97597 | <1% | 29 | $3K | |
| 81025 | <1% | 164 | $3K | |
| 87430 | <1% | 66 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 463 | $2K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 39 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 924 | $2K |
| 83690 | <1% | 471 | $2K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 229 | $2K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 29 | $2K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 28 | $1K |
| 83880 | <1% | 368 | $1K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 55 | $982.13 |
| 84484 | <1% | 1,483 | $748.49 | |
| 85027 | <1% | 1,103 | $697.63 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 644 | $475.87 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 31 | $465.94 |
| 87070 | <1% | 26 | $430.02 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 205 | $354.81 |
| 87186 | <1% | 392 | $277.35 | |
| 85610 | <1% | 713 | $266.57 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 413 | $230.87 |
| 80306 | <1% | 31 | $183.76 | |
| 85730 | <1% | 315 | $180.17 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 761 | $165.23 |
| 80061 | Lipid panel | <1% | 486 | $159.60 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 261 | $95.07 |
| J2704 | Injection, propofol, 10 mg | <1% | 129 | $83.76 |
| 83735 | <1% | 206 | $79.20 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 25 | $68.39 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 207 | $56.75 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 343 | $42.30 |
| 85007 | <1% | 34 | $36.66 | |
| 81003 | <1% | 19 | $30.50 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 28 | $27.83 |
| 86901 | <1% | 25 | $25.83 | |
| 86900 | <1% | 26 | $25.83 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 31 | $20.86 |
| 83605 | <1% | 15 | $15.85 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 18 | $15.31 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 19 | $12.60 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 56 | $9.24 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 36 | $5.88 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 31 | $5.18 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 12 | $3.78 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 54 | $2.52 |
| A9270 | Non-covered item or service | <1% | 10,072 | $1.77 |
| 82962 | 0% | 339 | $0.00 | |
| J3490 | Unclassified drugs | 0% | 59 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.